VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce the acceptance of an abstract to be presented at the 2022 AACR Special Conference on Sarcomas. The conference is being held May 9-12, 2022 in Montreal, Canada.
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
